FDA approval: Jideytro (Type 1 - New Molecular Entity)

AI Summary

The FDA approved zidesamtinib (Jideytro) as a new molecular entity on 22 July 2026. This regulatory action confirms that the sponsor's application met FDA's approval criteria; however, the approval notice itself does not disclose the clinical trial results, efficacy data, safety profile, or indication(s) that supported approval.

Plain-language summary

FDA approval of a new molecular entity (zidesamtinib) represents a regulatory action; the record does not contain clinical trial data or efficacy evidence.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

Clinicians should consult the full prescribing information (not provided in this record) for indication, dosing, contraindications, adverse events, and clinical evidence. This approval notice alone does not convey efficacy, safety comparative data, or clinical guidance.

Caveats

• This regulatory record does not contain clinical trial results, efficacy data, or safety summaries.
• The indication(s) for which zidesamtinib was approved are not stated in this record.
• No comparative efficacy, adverse event rates, or trial population demographics are reported.
• The underlying clinical rationale and trial designs supporting approval are not disclosed in this regulatory action notice.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.